Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Does the distribution pattern of brain metastases during BRAF inhibitor therapy reflect phenotype switching?

Melanoma research - 1 Jun 2017

Haueis Silvia A, Kränzlin Pascale, Mangana Joanna, Cheng Phil F, Urosevic-Maiwald Mirjana, Braun Ralph P, Levesque Mitchell P, Dummer Reinhard, Goldinger Simone M

Abstract excerpt

Brain metastases (brain mets) are frequent in metastatic melanoma patients. The aim of this study was to investigate the morphology and progression pattern of brain mets in melanoma patients treated with BRAF inhibitors (BRAFi) compared with patients who did not receive targeted therapy (BRAFi group and control group). The number and size of brain mets were compared between a baseline and a comparative MRI at...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Brain Neoplasms
Share to Follow-Up Studies

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Melanoma

Share to Neoplasm Invasiveness

Share to Neoplasms, Second Primary

Share to Protein Kinase Inhibitors

Share to Proto-Oncogene Proteins B-raf

Share to Survival Rate

Source

Identifiers

PMID: 28099366
DOI: 10.1097/CMR.0000000000000338

Genes

BRAF

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Does the distribution pattern of brain metastases during BRAF inhibitor therapy reflect phenotype switching?PMID 28099366Read ↗

BRAF-V600 mutational status affects recurrence patterns of melanoma brain metastasis.Semantic proximity Read ↗

Progression patterns under BRAF inhibitor treatment and treatment beyond progression in patients with metastatic melanoma.Semantic proximity Read ↗

Impact of BRAF inhibitors on surgical outcomes in melanoma brain metastases: Evidence from a multicenter observational study.Semantic proximity Read ↗

Clinical and radiological response of BRAF inhibition and MEK inhibition in patients with brain metastases from BRAF-mutated melanoma.Semantic proximity Read ↗

BRAF-MEK inhibition in melanoma brain metastases: a new hope.Semantic proximity Read ↗

BRAF V600 Mutation and BRAF Kinase Inhibitors in Conjunction With Stereotactic Radiosurgery for Intracranial Melanoma Metastases: A Multicenter Retrospective Study.Semantic proximity Read ↗

The mutational landscape of melanoma brain metastases presenting as the first visceral site of recurrence.Semantic proximity Read ↗

Activity and Resistance of a Brain-Permeable Paradox Breaker BRAF Inhibitor in Melanoma Brain Metastasis.Semantic proximity Read ↗

Correlation of MRI signal characteristics of intracranial melanoma metastases with BRAF mutation status.Semantic proximity Read ↗

Upfront targeted therapy for symptomatic melanoma brain metastases: paradigm changing?Semantic proximity Read ↗

BRAF/MEK Inhibition as a Bridge to Immunotherapy for Symptomatic BRAF V600 Melanoma Brain Metastases: A Case Series.Semantic proximity Read ↗

Rapid hyperacute intracranial deterioration following initiation of ipilimumab/nivolumab in BRAF V600E-mutant melanoma of unknown primary with brain metastases after BRAF/MEK inhibitor therapy: a case series.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.